Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Local estrogen treatment in patients with urogenital symptoms (CROSBI ID 104153)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Šimunić, Velimir ; Banović, Ivo ; Ciglar, Srećko ; Jeren, Lana, Pavičić Baldani, Dinka ; Šprem, Marina Local estrogen treatment in patients with urogenital symptoms // International journal of gynaecology and obstetrics, 82 (2003), 187-197. doi: 10.1016/S0020-7292(03)00200-5

Podaci o odgovornosti

Šimunić, Velimir ; Banović, Ivo ; Ciglar, Srećko ; Jeren, Lana, Pavičić Baldani, Dinka ; Šprem, Marina

engleski

Local estrogen treatment in patients with urogenital symptoms

Objective was to determine the efficacy and safety of low dose (25  g) micronized 17  -estradiol administered vaginally in the management of patients with urogenital symptoms. A total of 1612 patients with urogenital complaints were randomized to receive 25  g of micronized 17 -estradiol (828) or placebo (784) in a multicentric double-blind placebo controlled study running for 12 months. The women were treated once a day for two weeks, and then twice a week for the rest of the twelve months with the active or placebo tablet. The assessment included full history-questionnaire, micturition diary, gynecological and cystometric examination, transvaginal ultrasound and serum estradiol level determination. It was carried out at the beginning, and after four and twelve months of treatment. The overall success rate of micronized 17 -estradiol on subjective and objective symptoms of postmenopausal women with vaginal atrophy was 85.5%, and the effect of placebo was 41.4%. A significant improvement of urinary atrophy symptoms was determined in vaginal ERT group comparing with the beginning of the study (51.9% vs. 15.5%, p=0.001). Maximal cystometric capacity and the volume of the urinary bladder at which patients first felt urgency and strong desire to void were considerably larger after micronized 17 -estradiol treatment than before it. The number of patients with uninhibited bladder contractions significantly decreased after micronized 17 -estradiol compared with the values before the treatment or after placebo. Side effects were observed in 61 (7.8%) patients treated with low dose micronized 17- estradiol. We found that 25  g of micronized 17- estradiol do not raise serum estrogen level and do not stimulate endometrial growth. Local administration of 25  g of micronized 17- estradiol is effective and safe treatment option in the management of women with urogenital complaints.

local estrogen treatment ; efficacy ; safety ; urogenital symptoms

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

82

2003.

187-197

objavljeno

0020-7292

1879-3479

10.1016/S0020-7292(03)00200-5

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost